Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

CJC-1295 (DAC) peptide icon, one bubble per amino acidCJC-1295 (DAC)30 residuesYADAIFTQSYRKVLAQLSARKLLQDILSRKEach bubble = one amino acid. Size = residue mass. Color = chemical class.

CJC-1295 (DAC)

Beginner tier: 1 mg, weekly · 12w on / 4w off · community consensus

~8 days half-life·Injection

Also known as: CJC-1295 DAC, DAC:GRF, Tetrasubstituted GRF(1-29)-Ala15-Leu27-NH2-DAC

A single subcutaneous injection raised IGF-1 levels for 9 to 11 days straight in a 65-person Phase I trial. CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog that locks onto circulating albumin, stretching the half-life from minutes to roughly eight days. The convenience is real: one or two injections per week instead of daily. The catch is equally real. ConjuChem's Phase II trial was discontinued in 2006 after one patient death, and no Phase III has followed. Community adoption runs well ahead of the clinical evidence, with 300 to 600 Reddit threads tracking real-world results.

What Is CJC-1295 (DAC)?

Nine to 11 days of IGF-1 elevation from a single shot. That was the headline finding from Teichman and colleagues' Phase I trial [1] of CJC-1295 with DAC in 65 healthy adults across nine dose groups. The compound, also known by its Drug Affinity Complex designation (CAS 446262-90-4), is a modified GHRH(1-29) analog carrying a maleimido linker that covalently bonds to Cys34 on serum albumin after injection. That albumin hitchhike is the entire pharmacological story: it turns a peptide with a minutes-long half-life into one that persists for roughly eight days.

The practical appeal is obvious. Where Mod GRF 1-29 (the no-DAC version) demands one to three daily fasted injections, the DAC form requires only one or two weekly shots. Community protocols settled on 1,000 to 2,000 mcg per week, doses well below the 30 to 120 mcg/kg single-dose range used in Phase I. Across 300 to 600 dedicated Reddit threads, users consistently report improved sleep within the first two weeks, body composition changes by months two and three, and water retention that ranks as the most common complaint.

The science-to-practice gap here is larger than for most peptides. ConjuChem's Phase II trial for HIV-associated lipodystrophy stopped in 2006 following one participant death attributed to pre-existing coronary artery disease. No Phase III was attempted. The FDA's PCAC recommended against including CJC-1295 on the 503A bulk drug substance list in December 2024, closing the compliant US compounding route. What remains is a compound with solid single-dose PK data, strong community traction, and a clinical development program that never crossed the finish line.

How CJC-1295 (DAC) Works

CJC-1295 with DAC binds the GHRH receptor on pituitary somatotroph cells the same way native GHRH does. The difference is what happens after injection. A maleimido group built into the Drug Affinity Complex reacts with Cys34 on circulating serum albumin, forming a covalent bond within minutes of subcutaneous administration. That bioconjugation accomplishes two things: it shields the peptide from DPP-IV enzymatic cleavage (the reaction that destroys native GHRH in under 7 minutes) and it slows renal clearance because albumin is too large for glomerular filtration.

The result is an elimination half-life of approximately 5.8 to 8.1 days (Teichman 2006)[1]. GH area-under-curve increased 2 to 10 fold across dose groups in Phase I. Ionescu and Frohman tracked what this meant for pulsatile secretion [2] and confirmed that GH pulses persist during DAC administration. The pattern isn't identical to physiology, though; tonic between-pulse GH levels rise alongside pulse amplitude, creating what the community calls "GH bleed." Sackmann-Sala's group later mapped the downstream serum protein changes from this sustained GH/IGF-1 axis activation [3]. Whether that tonic elevation carries long-term consequences remains an open question with no clinical data to settle it.

CJC-1295 (DAC) Benefits

  • CJC-1295 DAC benefits center on sustained growth hormone axis activation with minimal injection burden.
  • Once-weekly dosing convenience. One or two subcutaneous injections per week replaces the daily (or twice-daily) schedule required by the no-DAC form.
  • IGF-1 elevation lasting 9 to 11 days after a single injection, confirmed in Phase I across nine dose groups of 65 participants (Teichman 2006)[1].
  • Improved sleep quality. Community reports across hundreds of Reddit threads consistently place better sleep depth and vivid dreams within the first one to two weeks of starting.
  • Body composition shifts by months two to three. Users describe reduced abdominal fat and improved muscle fullness; the mechanism tracks with GH-mediated lipolysis and protein anabolic signaling.
  • Complementary GH release when stacked with Ipamorelin. Combining GHRH (CJC-1295 DAC) with a GHRP (Ipamorelin) is the most common community protocol, producing amplified GH pulses without cortisol or prolactin elevation.
  • Accelerated connective tissue recovery. A lesser-known benefit; sustained IGF-1 drives collagen synthesis, and post-injury users report faster joint and tendon recovery during cycles.

CJC-1295 (DAC): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 7 key studies·Research only

Phase I (Teichman 2006, n=65) confirmed dose-dependent GH/IGF-1 elevation (2–3× baseline) sustained 9–11 days after a single SC injection.

Dosing studied: 30–120 mcg/kg single ascending doses in Phase I (≈2,250–9,000 mcg for 75 kg adult); no therapeutic weekly dose established clinically: community doses (1,000–2,000 mcg/week) are well below Phase I single-dose levels
Read the evidence (key study, limitations)

Phase II (HIV lipodystrophy) discontinued 2006 after one patient death (attributed to pre-existing CAD). No Phase III completed; no approved therapeutic indication.

Key Study

Teichman et al. 2006 (PMID 16352683): Phase I, n=65, 9 dose groups (30–120 mcg/kg); mean GH AUC increase 2–10×; IGF-1 elevation persisted 9–11 days

Limitations

No completed Phase III RCT; Phase II discontinued; no chronic weekly dosing PK data; antibody formation in subset of Phase II participants; no direct comparison to exogenous GH for body composition outcomes

Community Experience
Moderate
3.5/5
Based on ~300–600+ r/Peptides threads (CJC-1295 DAC specific)

Effective for once-weekly GH/IGF-1 elevation and body recomposition; favored for dosing convenience over no-DAC.

Community dosing: 1,000 mcg/week (beginner) to 2,000 mcg 2×/week (advanced)
Read the reports (what users report 4, common issues 4)

Polarizing: water retention and "GH bleed" (tonic vs. pulsatile debate) are top complaints. Product mislabeling a significant quality concern.

What users report (4)
  • Once-weekly injection convenience vs. daily no-DAC dosing
  • Sustained IGF-1 elevation throughout the week
  • Improved sleep quality typically reported within first 1–2 weeks
  • Body composition changes (fat loss, improved muscle fullness) by months 2–3
Common issues (4)
  • Water retention more pronounced and persistent than no-DAC form
  • "GH bleed" concern: tonic GHRH stimulation vs. physiological pulsatile pattern
  • Product mislabeling documented: no-DAC commonly sold as DAC (different MW: ~3.6 kDa DAC vs ~3.4 kDa no-DAC)
  • Side effects (edema, joint pain, neuropathy) persist 3–4 weeks after stopping due to 8-day half-life
Partially Aligned

Science confirms GH/IGF-1 elevation mechanism and 8-day half-life pharmacokinetics. Community weekly dosing protocols (1–2 mg/week) are extrapolated empirically: they were not tested in Phase I (which used single doses of 2,250–9,000 mcg). No clinical data exists for the community dose range specifically. Phase II discontinuation and FDA's advisory committee vote against a 503A listing create a larger science-to-practice gap than most GH secretagogues.

CJC-1295 (DAC) Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner1 mg
WeeklyTrack
Moderate2 mg
WeeklyTrack
Aggressive2 mg
2x/weekTrack
Note:

Reconstitution math for common vial sizes. A 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg per mL. For a 1,000 mcg dose, pull 40 units on a standard U-100 insulin syringe. For 2,000 mcg, pull 80 units. A 2 mg vial with 1 mL BAC water gives 2,000 mcg per mL; a 1,000 mcg dose is 50 units.

Timing matters less with DAC than with the no-DAC form. You don't need to fast before injection. Evening dosing before bed is preferred because it complements natural nocturnal GH secretion, but the sustained release means missing that window by a few hours changes nothing meaningful.

The thing most beginners miss is product verification. DAC synthesis requires maleimido-group bioconjugation chemistry that is far more complex than standard peptide production. Community mass spec testing has documented cases of no-DAC product sold as DAC. LC-MS/MS certificates of analysis tell the two apart; DAC molecular weight runs roughly 3.6 kDa versus 3.4 kDa for no-DAC. If your weekly injection doesn't hold IGF-1 raised for seven to nine days (testable with a mid-week blood draw), you may have the wrong compound.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Cycle to maintain pituitary sensitivity. The long half-life means steady-state is reached after 2-3 injections.

Calculate your CJC-1295 (DAC) dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

CJC-1295 (DAC) Protocols by Goal

beginnerCommunity12 weeks on, 4 weeks off
Loading / Maintenance
Wk 1–12
1,000 mcg · Once weekly · Subcutaneous

Expected: Modest sustained IGF-1 elevation; improved sleep quality within 1–2 weeks; gradual improvement in recovery and skin quality over 3–4 months

Monitor: Baseline IGF-1 + IGFBP-3; fasting glucose. Recheck at week 4 and week 12.

How to Use CJC-1295 (DAC)

  1. 1
    Step 1

    Reconstitute the lyophilized vial by adding bacteriostatic water slowly along the glass wall. For a 5 mg vial, add 2 mL BAC water (2,500 mcg/mL). For a 2 mg vial, add 1 mL (2,000 mcg/mL). Swirl gently; never shake. Allow 5 minutes for complete dissolution.

  2. 2
    Step 2

    Draw your dose with a 29 or 30 gauge insulin syringe (U-100 scale). Beginner: 1,000 mcg = 40 units from a 5 mg/2 mL vial, or 50 units from a 2 mg/1 mL vial. Moderate: 2,000 mcg = 80 units from a 5 mg/2 mL vial.

  3. 3
    Step 3

    Choose a subcutaneous injection site: lower abdomen (2 inches from the navel), outer thigh, or upper arm. Rotate sites each injection to prevent lipodystrophy.

  4. 4
    Step 4

    Pinch the skin, insert the needle at a 45 degree angle, inject slowly, hold for 5 seconds before withdrawing.

  5. 5
    Inject once weekly for beginner and moderate protocols

    For the advanced split protocol, inject Monday and Thursday evenings. Evening dosing before bed is preferred.

  6. 6
    Step 6

    Fasting is not required before injection (unlike the no-DAC form). However, avoiding a large meal within 30 minutes is reasonable.

  7. 7
    Step 7

    Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks. Keep away from light and temperature fluctuation.

Alternative Routes

Intramuscular (IM)

Same dose; potentially faster Tmax vs. SC but pharmacological difference negligible given 8-day half-life

Not studied for CJC-1295 DAC specifically. Given the long half-life dominates PK, the route difference is clinically minor. SC remains standard in all clinical and community protocols.

Mixing your own vial? Use the CJC-1295 (DAC) reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

CJC-1295 (DAC) Stacking Protocols

Works With

Avoid

CJC-1295 (No DAC)

Combining two GHRH analogs provides no additive benefit and risks GHRH receptor saturation. The short-acting form (no-DAC) is redundant while DAC is active; the two should not be used simultaneously.

Do not combine
Sermorelin

Redundant GHRH mechanism. Combining with CJC-1295 DAC risks GHRH receptor desensitization from cumulative tonic stimulation. Choose one GHRH analog per cycle.

Do not combine
Tesamorelin

Redundant GHRH mechanism; Tesamorelin is FDA-approved for HIV lipodystrophy: the same indication CJC-1295 DAC was trialed for. Combining is pharmacologically irrational.

Do not combine
Exogenous HGH (recombinant growth hormone)

Combining a GH secretagogue with exogenous HGH creates additive IGF-1 elevation significantly amplifying cancer risk, fluid retention, and metabolic side effects. Requires full medical supervision and IGF-1/IGFBP-3 monitoring if combined.

Estimated Cost

Generic / Research
Research-grade (underground market): $9–25/mg depending on product and quantity. Representative research-grade pricing: 5 mg vials ~$45–60 (~$9–12/mg); 2 mg vials ~$30–48 (~$15–24/mg). Full 12-week cycle at 2,000 mcg/week = 24 mg = 5× 5 mg vials ≈ $225–$275.
Compounded
US 503A/503B compounding unavailable: FDA PCAC recommended against 503A bulk drug list inclusion (Dec 4, 2024; docket FDA-2024-N-4777); no final rule published as of October 2026. CJC-1295 is absent from the 503B outsourcing facility list.

Pricing updated 2026-04-09

CJC-1295 (DAC) Side Effects

Water retention is the defining side effect of CJC-1295 DAC, and it is more persistent than with any short-acting GHRH analog. The eight-day half-life means that once edema sets in, it takes three to four weeks (three to four half-lives) to fully clear after the last injection. Reducing dose from 2,000 to 1,000 mcg per week is the standard first response. If puffiness, swollen fingers, or tight shoes persist at the lower dose, stopping the compound entirely and waiting out the washout period is the right call.

Joint pain and carpal tunnel symptoms represent the next tier of concern. These reflect raised synovial fluid from sustained GH activity. Community reports place carpal tunnel symptoms in a subset of users by months two to three, particularly at the aggressive 2,000 mcg twice-weekly protocol. Paresthesia (tingling or numbness in the extremities) appears related and tends to track with higher IGF-1 levels. If numbness progresses or becomes bilateral, that warrants stopping and medical evaluation, not dose adjustment.

Blood glucose disruption deserves direct attention. Growth hormone antagonizes insulin action. Sustained GH elevation from CJC-1295 DAC can impair glucose metabolism in anyone with pre-existing insulin resistance or pre-diabetes. Fasting glucose and HbA1c monitoring at baseline, mid-cycle, and end-of-cycle is not optional for this compound.

The Phase II trial discontinuation requires honest framing. One participant died following the 11th injection in ConjuChem's HIV lipodystrophy study in 2006. The attending physician attributed the death to pre-existing asymptomatic coronary artery disease, and no regulatory finding of causality was published. The company stopped development for commercial reasons. That single event does not constitute proof of cardiac toxicity, but the absence of follow-up trials means no one has systematically evaluated cardiac safety during chronic weekly dosing.

Injection site reactions are generally mild: transient redness, slight induration, occasional warmth. Facial flushing is less common with the DAC form than with Mod GRF 1-29.

Antibody formation was documented in a subset of Phase II participants. The clinical significance is unclear, but diminishing IGF-1 response over successive weeks, loss of early-cycle sleep benefits, or injection site hives may signal immune sensitization. The standard community response is cycling 12 weeks on, 4 weeks off.

Pregnancy and breastfeeding are absolute contraindications. Active cancer or any history of malignancy rules out use because sustained GH/IGF-1 elevation promotes cell proliferation. Diabetes, active pituitary tumors, acute critical illness, and hypersensitivity to GHRH analogs are all contraindications that should not be worked around.

Common Issues & Solutions

Water retention: if significant edema develops, reduce dose from 2,000 to 1,000 mcg/week first; if persistent, reduce injection frequency. The 8-day half-life means edema takes 2–3 weeks to fully resolve after dose reduction.

Product mislabeling: DAC form has MW ~3.6 kDa vs. no-DAC ~3.4 kDa: only a mass spec CoA (not HPLC purity alone) tells them apart. Community testing has documented no-DAC substitution in multiple research-grade products. DAC will hold serum IGF-1 elevated for 9–11 days post-injection; no-DAC will not.

Side effects persist after stopping: the 8-day half-life means water retention, joint pain, and paresthesia symptoms can persist 3–4 weeks (3–4 half-lives) after last injection. Do not restart until symptoms fully resolve.

IGFBP-3 gap: IGF-1 alone is insufficient monitoring. Elevated IGF-1 with low IGFBP-3 elevates free IGF-1 disproportionately, increasing cancer signaling risk. Always test IGF-1 and IGFBP-3 together and assess the molar ratio.

"GH bleed" concern: Ionescu & Frohman 2007 [2] confirmed pulsatile GH persists during DAC administration: the concern is elevated tonic baseline, not abolishment of pulses. Cycling 12 weeks on / 4 weeks off is the standard response; no clinical data confirms or refutes GHRH receptor downregulation in humans from weekly dosing.

Ask AI about this page

Ask AI for a second opinion on CJC-1295 (DAC) dosing and side effects

Contraindications

  • Active cancer or history of malignancy: sustained GH elevation promotes cell proliferation
  • Diabetes mellitus: prolonged GH release antagonizes insulin and may worsen glycemic control
  • Pregnancy or breastfeeding
  • Active pituitary tumors or other intracranial neoplasms
  • Hypersensitivity to GHRH analogs or any component of the formulation
  • Acute critical illness: elevated GH during critical illness is associated with increased mortality

Drug Interactions

  • Insulin and oral hypoglycemics: sustained GH release antagonizes insulin action; frequent blood glucose monitoring required
  • Corticosteroids: chronic use blunts GH response and counteracts anabolic benefits
  • Other GH secretagogues (GHRP-2, GHRP-6, sermorelin): additive GH release increases side effect risk; avoid stacking without medical supervision
  • Thyroid hormones: GH accelerates T4-to-T3 conversion; monitor thyroid function during use
  • Anticoagulants (warfarin, heparin): albumin binding may theoretically alter drug displacement; monitor INR
  • CYP450-metabolized drugs: GH may alter hepatic clearance of CYP3A4 substrates
  • Combining two GHRH analogs provides no additive benefit and risks GHRH receptor saturation. The short-acting form (no-DAC) is redundant while DAC is active; the two should not be used simultaneously.
  • Exogenous HGH (recombinant growth hormone)

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1Baseline (before first injection); week 4; week 12 (end of cycle); 4 weeks into off-cycleUpper-normal for age/sex (avoid exceeding 97th percentile for age); standard reference ranges vary by lab
IGFBP-3Same timing as IGF-1: always test togetherIGF-1/IGFBP-3 molar ratio should remain within normal physiological range; flagging indicated if IGF-1 elevated but IGFBP-3 below mid-normal
Fasting glucose and HbA1cBaseline; week 6; end of cycleFasting glucose <100 mg/dL; HbA1c <5.7%
Thyroid panel (TSH, fT4, fT3)Baseline; end of cycle (week 12)Not listed
IGF-1

Primary pharmacodynamic marker for GH axis activation; confirms compound authenticity and dose adequacy

IGFBP-3

IGFBP-3 binds and buffers free IGF-1; low IGFBP-3 + elevated IGF-1 = disproportionately elevated free IGF-1 with increased cancer signaling risk; IGF-1 alone is insufficient assessment

Fasting glucose and HbA1c

GH antagonizes insulin action; sustained GH elevation can impair glucose metabolism, particularly in individuals with pre-diabetes or insulin resistance

Thyroid panel (TSH, fT4, fT3)

GH accelerates peripheral T4-to-T3 conversion; can unmask subclinical hypothyroidism or alter thyroid hormone ratios in users on thyroid medication

CJC-1295 (DAC) Before and After

Week 1-2

Improved sleep quality and mild water retention as GH and IGF-1 levels rise. Sustained GH elevation begins within hours of first injection.

Weeks 3-4

Recovery between training sessions improves. Skin hydration and quality begin to improve. Energy and mood stabilize.

Months 2-3

Visible body composition changes: reduced abdominal fat, improved muscle fullness. Joint and connective tissue recovery accelerates.

Months 3-4

Peak anti-aging and body composition benefits. Sustained fat loss with preserved lean mass. Hair and nail growth may accelerate.

Month 5+

Benefits plateau. Cycle off for 4 weeks to restore pituitary sensitivity before restarting.

What to Expect

Week 1 to 2: GH levels start climbing within hours of the first injection. IGF-1 follows by day three or four, peaking around day seven to nine. Most users notice deeper sleep and vivid dreams first. Mild puffiness and water retention show up by day four or five; occasional headache is possible but less common than with the no-DAC form.

Weeks 3 to 4: Steady-state IGF-1 approaches after two to three weekly injections. Recovery between training sessions picks up noticeably. Skin hydration and texture improve. Water retention either stabilizes or needs dose management. Some users report tingling in fingers and toes at this stage.

Months 2 to 3: Body composition changes become visible. Abdominal fat decreases, muscle fullness improves, and connective tissue recovery accelerates. Sackmann-Sala's group [3] documented serum protein profile shifts consistent with sustained GH/IGF-1 axis activation during this window. Hair and nail growth speed up. Carpal tunnel symptoms appear in a subset of users; blood glucose may shift if not monitored.

Months 3 to 4: Anti-aging and body composition benefits hit their peak. Fat loss continues with preserved lean mass. Joint and connective tissue recovery remains strong. GH-related side effects (edema, paresthesia) tend to be most pronounced here. Insulin sensitivity may decrease, making glucose monitoring more important.

Month 5 and beyond: Benefits plateau. The standard move is cycling off for four weeks to restore GHRH receptor sensitivity. Most side effects resolve within three to four weeks of stopping. Users commonly report significant water loss in the first seven to ten days off-cycle. No clinical data confirms or refutes the specific 12-on/4-off timing, but antibody formation documented in Phase II participants supports periodic breaks.

Detailed Timeline: Science vs Community

Week 1–2
Science

GH AUC increases within hours of first injection (Teichman 2006); IGF-1 begins rising by day 3–4. Peak IGF-1 at approximately day 7–9 post-injection.

Community

Improved sleep depth and vivid dreams. Mild puffiness/water retention beginning by day 4–5. Some users report mild headache or joint fluid increase.

Weeks 3–4
Science

Steady-state IGF-1 levels approaching after 2–3 weekly injections. GH axis running at elevated tonic + preserved pulsatile pattern.

Community

Faster recovery between training sessions. Improved skin hydration and texture noted. Some users report improved mood and energy. Water retention may stabilize or require dose management.

Months 2–3
Science

Sustained IGF-1 elevation drives GH-mediated lipolysis and protein anabolic signaling. Serum protein profile changes documented in Sackmann-Sala 2009 (PMID 19386527).

Community

Reduced abdominal fat, improved muscle fullness, connective tissue improvement. Hair and nail growth acceleration commonly noted.

Months 3–4
Science

No clinical data at 3–4 months from sustained weekly protocols; extrapolated from GH/IGF-1 axis physiology.

Community

Full anti-aging and body composition benefits established. Sustained fat loss with preserved lean mass. Joint and connective tissue recovery continues.

Month 5+ / Off-cycle
Science

No clinical data on benefit plateau timeline. Antibody formation documented in Phase II participants: clinical relevance for weekly chronic dosing unknown.

Community

Benefits plateau at this stage. Cycle off 4 weeks to restore GHRH receptor sensitivity. Most side effects resolve within 3–4 weeks of stopping. Many users report significant water loss in first 7–10 days off-cycle.

Pharmacokinetics

Half-Life
192h
Bioavailability
SC: estimated 90%+ due to albumin binding preventing degradation
Tmax
2-4 hours (GH peak after SC injection)
Data Confidence
moderate

Source: Estimated t½ 5.8-8.1 days via albumin bioconjugation (Teichman et al. 2006 PMID 16352683)

Pharmacokinetics: Active Dose Over Time

t½ = ~8 days

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
30
Molecular Weight
3,647.25 Da
Sequence
YADAIFTQSYRKVLAQLSARKLLQDILSRK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider CJC-1295 (DAC)

  • Adults over 30 with age-related GH decline (somatopause) seeking sustained GH support
  • Athletes and bodybuilders wanting steady GH elevation with minimal injection frequency
  • Adults seeking improved body composition with once-weekly dosing convenience
  • Individuals with poor sleep quality and slow recovery between training sessions
  • Post-injury patients wanting prolonged GH-mediated tissue repair

Related Peptides

What Changed for CJC-1295 (DAC)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Pulsatile Secretion of GH Persists During Continuous Stimulation by CJC-1295 (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, stable up to 12 months
After Reconstitution
Refrigerate, use within 4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

This is the core pharmacological debate. Ionescu & Frohman 2007 (PMID 17018654) showed pulsatile GH secretion persists during CJC-1295 DAC administration; the tonic GHRH receptor activation doesn't fully abolish the natural pulse but does raise the baseline. Long-term receptor downregulation data in humans is absent; cycling off for 4+ weeks after 12 weeks is the standard community response.

Per Ionescu & Frohman 2007 (PMID 17018654), pulsatile GH secretion persists during DAC treatment; pulse amplitude increases while the tonic between-pulse level also rises. It's not a flat line, but meaningfully different from the sharp/narrow pulsatile pattern of the no-DAC version.

Given the 8-day half-life, daily dosing of 1,000 mcg would accumulate to ~7,000–8,000 mcg steady-state. Side effects (water retention, joint pain, carpal tunnel) would be significant and persistent for 3–4 weeks post-stoppage as the compound clears.

ConjuChem's Phase II trial for HIV-associated lipodystrophy was halted in 2006 after one patient died following their 11th injection. The attending physician attributed the death to pre-existing asymptomatic coronary artery disease, not the compound. No formal regulatory finding of causality was published. The company discontinued development for commercial reasons.

Split dosing (1,000 mcg twice-weekly) produces more stable plasma levels with a smaller peak-to-trough swing. Once-weekly dosing creates a higher Cmax followed by a longer trough. No head-to-head human study exists, but split dosing is generally preferred for more consistent IGF-1 elevation.